By clicking to watch this video, you agree to our privacy policy.
On February 25, 2022, SFARI held an informational session about the 2022 Human Cognitive and Behavioral Science request for applications (RFA).
About the Session
The 2022 Human Cognitive and Behavioral Science RFA opened on February 7, 2022. This RFA aims to support the unique opportunities and challenges inherent to studies that directly involve participants with autism spectrum disorder (ASD).
This RFA prioritizes research that produces foundational knowledge about the neurobehavioral differences associated with ASD. Many of these projects are expected to inform or relate to the development and refinement of tools needed for translational efforts, such as biomarkers and outcome measures. Special emphasis is placed on objective, quantitative measures that may be used in conjunction with standardized clinical measures and genomic information to better triangulate phenotypic and neurobiological variability within and across individuals with ASD.
Members of the SFARI science team, including Pamela Feliciano, LeeAnne Green Snyder, Alice Luo Clayton and Paul Wang, held an informational session to answer questions about this new RFA.
About the Speakers
Pamela Feliciano is scientific director of SPARK and a senior scientist at SFARI. She oversees the recruitment and retention of participants in SPARK as well as the research priorities of the program. She also oversees several autism genetics and clinical grants in SFARI’s portfolio, with a particular emphasis on the development of objective, quantitative methods of measuring clinically relevant autism behaviors.
LeeAnne Green Snyder is a clinical research scientist at SFARI. She advises on protocol design, outcome measures and database needs for SFARI’s research cohorts of individuals with autism, including SPARK, the Simons Simplex Collection and Simons Searchlight.
Alice Luo Clayton is a senior scientist at SFARI. Her role involves managing programs related to neural circuits and behavior in animal models and human cohorts. She contributes to the development and availability of rat models of autism, as well as overseeing the Bridge the Independence Award program.
Paul Wang is deputy director of Clinical Research Associates, LLC, which is an affiliate of the Simons Foundation. His responsibilities focus on the development of arbaclofen for clinical use in ASD. He also helps support other Simons Foundation research initiatives, especially those with clinical facets.
Questions? Email: [email protected]
